Statement: Both cohorts of the primary trial reported the same number of patients vomiting during the trial.
Primary_evidence: Adverse Events 1:   Total: 22/79 (27.85%)   Anaemia 0/79 (0.00%)   Right ventricular dysfunction 1/79 (1.27%)   Diarrhoea 1/79 (1.27%)   Vomiting 2/79 (2.53%)   Abdominal pain 0/79 (0.00%)   Colonic obstruction 0/79 (0.00%)   Dysphagia 1/79 (1.27%)   Nausea 1/79 (1.27%)   Mucosal inflammation 1/79 (1.27%)   Performance status decreased 1/79 (1.27%)   Sudden death 1/79 (1.27%) Adverse Events 2:   Total: 13/76 (17.11%)   Anaemia 1/76 (1.32%)   Right ventricular dysfunction 0/76 (0.00%)   Diarrhoea 0/76 (0.00%)   Vomiting 2/76 (2.63%)   Abdominal pain 1/76 (1.32%)   Colonic obstruction 1/76 (1.32%)   Dysphagia 0/76 (0.00%)   Nausea 1/76 (1.32%)   Mucosal inflammation 0/76 (0.00%)   Performance status decreased 0/76 (0.00%)   Sudden death 0/76 (0.00%)